AnaptysBio reports $1B Jemperli sales, FDA approval for rectal cancer, and ongoing GSK litigation update
AnaptysBio announced $1 billion in global net sales for Jemperli through September 2026, marking 29% growth year-over-year. Jemperli received FDA approval as the first immunotherapy for adults with stage II and III MSI-H/dMMR locally advanced rectal ...
